title: An Overview of the Changing Landscape of Treatment for Advanced Melanoma.
abstract: Melanoma-the deadliest form of skin cancer-leads to thousands of deaths each year. Although melanoma is less common than basal cell and squamous cell skin cancers, melanoma is more dangerous because it is more likely to spread to other parts of the body, such as lymph nodes, if not diagnosed and treated early. Data from the National Cancer Institute indicate a steady rise in new cases of melanoma and, unfortunately, a steady rate in the number of deaths through 2013. Ninety percent of melanomas are linked to inadequate sun protection from ultraviolet rays or the tanning habits of young adults. Over the past 5 years, however, there have been a variety of new pharmacologic treatments for advanced melanoma including immunotherapy, targeted agents (BRAF and MEK inhibitors), and oncolytic viral therapy. In this article, we review the current literature on the treatment of melanoma, with a focus on emerging therapies.
authors.affiliation: Department of Clinical Health Professions, College of Pharmacy and Health Sciences, St. John's University, Queens, New York.
authors.forename: Chung-Shien
authors.initials: CS
authors.lastname: Lee
authors.affiliation: Oncology, Department of Pharmacy, James H. Quillen VA Medical Center, Mountain Home, Tennessee.
authors.forename: Christan M
authors.initials: CM
authors.lastname: Thomas
authors.affiliation: Department of Clinical Health Professions, College of Pharmacy and Health Sciences, St. John's University, Queens, New York.
authors.forename: Kimberly E
authors.initials: KE
authors.lastname: Ng
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008545:Melanoma / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D050130:Oncolytic Virotherapy / Q000379:methods; D012878:Skin Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents
keywords: BRAF inhibitors; CTLA4 inhibitor; MEK inhibitors; PD1 inhibitors; immunotherapy; melanoma